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Abstract SecYEG forms the protein-conducting channel of the
Escherichia coli translocase. It binds the peripheral ATPase
SecA that drives the preprotein translocation reaction. PrlA4 is a
double mutant of SecY that enables the translocation of
preproteins with a defective or even missing signal sequence.
The effect of the individual mutations, F286Y and I408N, was
studied with SecYEG proteoliposomes. SecY(I408N) is respon-
sible for the increased translocation of preproteins with a
defective and normal signal sequence, and exhibits a stronger
prl phenotype than PrlA4. This activity correlates with an
elevated SecA-translocation ATPase and SecA binding affinity.
SecY(F286Y) supports only a low SecA binding affinity,
preprotein translocation and SecA translocation ATPase activ-
ity. These results suggest that the second site F286Y mutation
reduces the strength of the I408N mutation of PrlA4 by lowering
the SecA binding affinity. ß 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Escherichia coli translocase consists of an oligomeric assem-
bly of the heterotrimeric SecYEG integral membrane protein
complex and the peripheral ATPase SecA (reviewed in [1]).
SecA binds with high a⁄nity to SecYEG [2,3]. By multiple
cycles of ATP binding and hydrolysis, SecA drives the step-
wise translocation of the preprotein across the membrane, a
process that is accelerated by the proton motive force [4^7].
The N-terminal signal sequence of preproteins is important
for their targeting to SecA [8,9]. Genetic studies have identi-
¢ed mutations in secY (prlA), secE (prlG), secA (prlD) and
secG (prlH) that permit the translocation of preproteins with
a defective, or even missing, signal sequence [10^14]. Prl mu-
tations (protein localization) do not directly restore the rec-
ognition of the signal sequence, but instead disrupt a proof-
reading activity which results in broadened selectivity of the
translocase [15]. PrlA and prlG mutants appear to function by
similar mechanisms [13], while PrlD mutants seem to act dif-
ferently [16].
Most of the insights in the mechanism of signal sequence
suppression are derived from studies on PrlA4 [17]. Previ-
ously, we have shown that PrlA4 supports an increased
SecA binding a⁄nity both in the presence and absence of
ATP. This results in a stabilization of the SecA^preprotein
complex at the membrane, and consequently, a more e⁄cient
initiation of translocation [18]. Therefore, the prlA mutation
not only reduces the need for a proper signal sequence but
also improves translocation of normal preproteins. Due to the
increased SecA binding a⁄nity, the proton motive force de-
pendency of the translocation is reduced [19]. The PrlA4 mu-
tant has a di¡erent conformation that a¡ects the protease-
sensitivity of SecA [20]. PrlA and PrlG mutants are more
unstable than wild-type SecYEG in L-octylglucopyranoside
(OG) detergent solution [21].
PrlA4 is a double mutant that harbors the F286Y mutation
in transmembrane segment 7 (TMS7) and I408N in TMS10.
The latter is responsible for the suppressor phenotype [22], but
cannot be stably maintained in E. coli without second site
mutations such as F286Y (PrlA4) or S188L (PrlA6) [15,21].
This seems to be a common feature with strong prlA mutants,
but the molecular mechanism by which these second site mu-
tations work is not understood. Here, we have studied the
contribution of the individual mutations to the PrlA4 phe-
notype using proteoliposomes reconstituted with puri¢ed
SecYEG complex.
2. Materials and methods
2.1. Materials
SecA, SecB, proOmpA, and SecYEG were puri¢ed as described
[23]. SecYEG was reconstituted into liposomes of E. coli phospholip-
ids (Avanti polar lipids, Alabaster, AL, USA) by detergent dilution
[23]. SecA and proOmpA were labeled with 125I (Radiochemical
Centre, Amersham, UK) using Iodo-Beads (Pierce, IL, USA). 35S-
labeled v8-proOmpA was synthesized from plasmid pET2336 using
the E. coli T7 S30 Extract System for Circular DNA (Promega, Mad-
ison, WI, USA). Inner Membrane Vesicles (IMVs) were obtained as
described [24] and treated with a polyclonal SecA antibody to remove
the endogenously bound SecA [18,25]. Detergent dodecylmaltoside
(DDM) was from Anatrace (Maumee, OH, USA).
2.2. Plasmids
To facilitate cloning, the NcoI site between the secY and secE genes
was removed from pET610 [24] by PCR, yielding pET2302.
SecY(I408N,F286Y), SecY(F286Y) and SecY(I408N) were introduced
into pET2302 by PCR mutagenesis resulting in pET2306, pET2307
and pET2308, respectively. v8-proOmpA was placed behind a T7
promoter by transferring the HindIII/EcoRI fragment from pET25
[18] into HindIIIUEcoRI-digested pBS2KS, yielding pET2336. All
constructs were con¢rmed by sequencing.
2.3. Other techniques
In vitro translocation of [125I]proOmpA or [35S]v8-proOmpA into
0014-5793 / 02 / $22.00 ß 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 3 2 1 3 - 6
*Corresponding author. Fax: (31)-50-3632154.
E-mail address: a.j.m.driessen@biol.rug.nl (A.J.M. Driessen).
FEBS 25599 17-12-01
FEBS 25599 FEBS Letters 510 (2002) 17^21
proteoliposomes was assayed by its accessibility to added proteinase
K [26]. Translocation reactions were analyzed by SDS^PAGE and
autoradiography. Binding of SecA to IMVs was assayed essentially
as described [2]. The SecA ATPase activity was assayed as described
[27].
3. Results
3.1. Strong signal sequence suppressor activity of SecY(I408N)
is tempered by the second mutation, F286Y
To dissect the function of the two mutations in the PrlA4
signal suppressor mutant, I408N and F286Y were separately
introduced into SecY and cloned into a vector that allows
high-level overexpression of His6-tagged SecYEG. Wild-type
SecYEG and SecY(F286Y)EG were overproduced to similar
levels, but the expression of SecY(I408N)EG was severely
reduced as indicated by the levels in the membranes (Fig.
1A). Re-introduction of F286Y into the I408N mutant
( = PrlA4) restored the overexpression to the level found for
wild-type SecYEG. The SecYEG complexes were puri¢ed and
reconstituted into proteoliposomes (Fig. 1B). Prl mutations
have been reported to weaken the association between SecY,
SecE and SecG [21]. Since the puri¢cation method relies on
the co-puri¢cation of SecE and SecG with His6-tagged SecY
[23], the possibility existed that due to the weakened interac-
tion, the mutant SecYEG complexes dissociate. However,
SDS^PAGE, silver staining and Western blotting (Fig. 1B)
showed that this was not the case. Proteoliposomes contained
equal amounts of SecY, SecE and SecG. The I408N mutation
caused an aberrant migration of SecY on SDS^PAGE (Fig.
1). Such behavior on SDS^PAGE is indicative of an altered
conformation of SecY as the net charge is not a¡ected by the
mutation.
Proteoliposomes were analyzed for proOmpA-stimulated
SecA (translocation) ATPase activity. Translocation ATPase
was V6-fold higher with SecY(I408N)EG as compared to the
wild-type, and even exceeded that of the PrlA4 mutant (Fig.
2A). The basal SecA ATPase in the absence of proOmpA was
also higher with SecY(I408N) and PrlA4 proteoliposomes.
Strikingly, the F286Y mutation dramatically reduced the
translocation ATPase activity to less than 15% of the wild-
type. In vitro translocation assays using chemical amounts of
125I-labeled proOmpA showed a similar pattern. SecY-
(I408N)EG supported the highest activity, while the SecY-
(F286Y)EG complex was ¢ve- to eight-fold less active than
the wild-type (Fig. 2B). To analyze the signal sequence sup-
pressing activity, the translocation of v8-proOmpA was as-
sayed. v8-proOmpA carriers a deletion of the isoleucine at
position 8 of the signal sequence, which results in a major
translocation defect in vivo [28]. Likewise, v8-proOmpA is
poorly translocated in vitro, but the translocation defect can
be suppressed by PrlA4 mutant [18]. Since v8-proOmpA is
poorly translocated, radiochemical amounts of 35S-labeled
v8-proOmpA were synthesized in vitro to allow for a sensitive
detection of translocation in vitro. Again, SecY(I408N)EG
supported the highest activity, while SecY(F286Y)EG proteo-
liposomes showed no measurable translocation of v8-proOm-
pA (Fig. 2B). As observed previously [29], reconstituted wild-
type SecYEG translocates low amounts of v8-proOmpA (Fig.
2A). This activity likely originates from the high levels of
SecA and SecYEG present in the assay [18]. In vivo studies
have shown that signal sequence mutants, and even deletions,
are somewhat leaky and can be translocated to a small extent
by wild-type SecYEG [14,30]. In this respect, high amounts of
SecA or SecYEG can suppress signal sequence defects in vivo
[16] and in vitro [18]. Taken together, the results demonstrate
that the SecY(I408N) is a stronger signal sequence suppressor
than PrlA4, while the F286Y mutation dramatically reduces
the activity of SecYEG. When combined with the I408N mu-
tation, F286Y tempers the Prl activity of the SecY(I408N)EG
complex.
3.2. Reconstituted PrlA4 and SecY(I408N)EG complexes are
not thermolabile
Octylglucoside-solubilized SecYEG complex is thermolabile
[31]. Prl mutations render the complex even more thermola-
bile, causing it to dissociate in detergent solution already at
37‡C [21]. This thermolability has been attributed to a loos-
ened interaction between the SecYEG subunits [21]. Since prl
mutants are not temperature-sensitive in vivo [32], it appears
that the thermolability is detergent-induced. Unlike OG, the
DDM is capable of preserving the SecA^SecYEG interaction
[33]. Therefore, the thermostability of the DDM-solubilized
and reconstituted SecYEG complexes were compared.
DDM-solubilized SecYEG was incubated at 37‡C for up to
30 min, reconstituted into proteoliposomes, and the remaining
SecA translocation ATPase activity was determined (Fig. 3).
Fig. 1. Overexpression and puri¢cation of wild-type and mutant
SecYEG complexes. A: Isolated inner membrane vesicles containing
overexpressed wild-type SecYEG, PrlA4, SecY(F286Y)EG or Sec-
Y(I408N)EG were analyzed by SDS^PAGE and CBB staining.
B: Proteoliposomes containing puri¢ed wild-type SecYEG, PrlA4,
SecY(F286Y)EG or SecY(I408N)EG were analyzed by SDS^PAGE
and silver staining or by immunoblotting using an antibody against
SecE.
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Wild-type SecYEG and SecY(F286Y)EG retained more than
50% of their activity after 30 min incubation at 37‡C in
DDM, while PrlA4 and SecY(I408N)EG were readily inacti-
vated under these conditions (Fig. 3A), con¢rming the pre-
vious observations in OG [21]. However, the wild-type and
mutant SecYEG complexes reconstituted in proteoliposomes
were completely stable when incubated at 37‡C (data not
shown) and 47‡C (Fig. 3B). Similar results were obtained
with IMVs (data not shown). The activity of SecY(F286Y)
increased two-fold, but this is only a marginal e¡ect as the
activity is low (Fig. 1A). Therefore, the thermolability of PrlA
Fig. 2. Activity of puri¢ed wild-type and mutant SecYEG complexes. A: SecA ATPase in proteoliposomes in the absence (white bars) or pres-
ence (black bars) of proOmpA. B: Translocation of [125I]proOmpA and [35S]v8-proOmpA into proteoliposomes (5 and 20 Wg/ml, respectively)
in the presence of 10 Wg/ml SecA and 2 mM ATP. Note that with proOmpA, chemical amounts of 125I-labeled preprotein were used, whereas
the v8-proOmpA was synthesized in vitro with a transcription/translation system to yield radiochemical amounts of 35S-labeled preprotein.
Therefore, the translocation e⁄ciencies of these two preproteins cannot be compared directly.
Fig. 3. Thermolability of detergent-solubilized and reconstituted
wild-type and mutant SecYEG complexes. A: DDM-solubilized Sec-
YEG (a), PrlA4 (b), SecY(F286Y)EG (E) or SecY(I408N)EG (F)
were incubated at 37‡C for the times indicated. The residual activity
was measured after reconstitution in E. coli lipids as proOmpA-
stimulated SecA-ATPase activity and plotted as a percentage of the
activity prior to the preincubation at 37‡C. B: Reconstituted Sec-
YEG (a), PrlA4 (b), SecY(F286Y)EG (E) or SecY(I408N)EG (F)
were incubated at 47‡C for the times indicated. The residual SecA
translocation ATPase activity was plotted as described for (A).
Fig. 4. Scatchard analysis of SecA binding to wild-type and mutant
SecYEG complexes. [125I]SecA (0.5^125 nM) binding to inner mem-
brane vesicles (50 Wg/ml) containing overexpressed wild-type Sec-
YEG (A), PrlA4 (B), SecY(F286Y)EG (C) or SecY(I408N)EG (D)
in the presence (a) or absence (b) of 2 mM ATP. Data were not
corrected for background and low a⁄nity SecA binding.
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mutants as observed in detergent solution is not manifested
when the enzyme is present in the lipid membrane.
3.3. I408N mutation is responsible for the increased
SecA binding a⁄nity of PrlA4
PrlA4 exhibits an increased binding a⁄nity for SecA as
compared to the wild-type [18]. To determine which of the
two mutations is responsible for this phenomenon, SecA bind-
ing experiments were performed. IMVs containing overpro-
duced wild-type and mutant SecYEG complexes were used
as similar binding experiments with proteoliposomes are ham-
pered by the high levels of SecA binding to the lipid surface.
SecA binding to wild-type SecYEG in the absence and pres-
ence of ATP occurred with a Kd of 4 and 13 nM, respectively
(Fig. 4A). PrlA4 binds SecA with a much higher a⁄nity (Kd
V1.3 nM) that is barely a¡ected by ATP (Kd V1.6 nM) (Fig.
4B). Strikingly, the SecY(I408N) mutant binds SecA tighter
(Kd of 0.8^1.0 nM) (Fig. 4D). In the presence of ATP, its
binding a⁄nity for SecA (Kd V1.0 nM) is even up to 13-
fold higher compared to the wild-type. The convex appear-
ance of the Scatchard plots of PrlA4 and SecY(I408N)EG
(Fig. 4B,D) is due to the low a⁄nity binding of SecA to the
lipid surface. SecY(F286Y)EG binds SecA (Kd of 8 nM) with
a two-fold lower a⁄nity than wild-type SecYEG (Fig. 4C).
The a⁄nity is further reduced by ATP (Kd V20 nM) which
makes it a very poor binding partner for SecA. These data
indicate that I408N is responsible for the increased SecA bind-
ing a⁄nity of PrlA4, while the second site mutation, F286Y
partially reverses this e¡ect.
4. Discussion
In this report, we have analyzed the contribution of the
F286Y and I408N mutations to the phenotype of PrlA4 using
IMVs and proteoliposomes reconstituted with the puri¢ed
SecYEG complex. Our in vitro studies con¢rm previous in
vivo results that show that the I408N mutation is responsible
for the suppressor phenotype [22]. The suppressor phenotype,
as manifested by the translocation of a signal sequence defec-
tive proOmpA derivative, is accompanied by an increased
translocation of the wild-type proOmpA and correlates with
a dramatically improved SecA-binding a⁄nity. Strikingly,
SecY(I408N) not only exhibits a much stronger prl activity
than PrlA4, but it is also more e¡ective in binding SecA
both in the presence and absence of ATP. In contrast, the
second mutation, F286Y, markedly reduces the SecA binding
a⁄nity and supports only a low translocation and SecA-ATP-
ase activity. Since I408N and F286Y a¡ect the binding of
SecA in an opposite manner, we propose that the second
site mutation tempers the prl phenotype by reducing the
SecA binding a⁄nity of SecY(I408N). Strong prlA mutations
are often accompanied by a second site mutation [13,15]. Such
mutations may function by a similar mechanism as F286Y in
PrlA4.
We have previously shown that the I278C mutation in
TMS7 confers a suppressor phenotype and increases the af-
¢nity for SecA [29]. The F286Y mutation of PrlA4 localizes in
the same TMS, but reduces the SecA binding a⁄nity (this
paper). It is of interest to note that in a regular K-helix,
I278 and F286 are predicted to be located on same site of
the helix. Recently, the sites of interaction between TSMs of
SecY and SecE have been mapped by cysteine scanning muta-
genesis [37]. These data suggest that I278 and F286 are part of
a helical face that points away from TMS3 of SecE. Many
mutations have been described in SecY that cause either a
strong or weak signal sequence suppression phenotype. These
mutations are not only con¢ned to TMS7 and TMS10, but
can also be found in TMS2, periplasmic loop 1 and, less
frequently, in other parts of the protein. Although mutations
in the other regions have not been studied in detail, it is likely
that they also alter the SecA binding a⁄nity of SecY.
Prl mutants are less thermostabile in detergent solution
than the wild-type SecYEG complex, and readily dissociate
upon prolonged incubation at 37‡C [21]. The exact mecha-
nism of inactivation is unclear, as a functional SecYEG com-
plex can be reconstituted from the individual SecY, SecE and
SecG subunits [34,35]. The low expression of SecY(I408N)EG
compared to PrlA4 (Fig. 1A) points to a reduced stability.
Although SecY(I408N) is a stronger Prl suppressor than
PrlA4, the proteins did not di¡er signi¢cantly in thermolabil-
ity in detergent solution ([21], this study). Therefore, the re-
storation of overexpression of SecY(I408N) by F286Y cannot
be explained by an e¡ect of F286Y on the (thermo-)stability
of the PrlA4 complex. Thermal inactivation of SecYEG in
detergent solution is accompanied by a dissociation of the
complex. This has been taken to suggest that a loosened
SecY^SecE interaction is responsible for the prl phenotype
[21]. Hypothetically, the Prl phenotype would emerge from a
relaxation of a putative signal sequence binding site on
SecYEG, rendering the complex less stringent in accepting
preproteins with defective signal sequences. The transmem-
brane SecY^SecE contact surface would be part of such a
signal sequence binding site. It is, however, important to
note that current biochemical evidence in favor of such a
speci¢c signal sequence binding site on SecYEG is weak as
the helical contacts between SecY and SecE persist when a
preprotein inserts into the translocation channel in an ATP-
and SecA-dependent manner [24,37]. Moreover, the model
does not readily account for the translocation of preproteins
without a signal sequence [14,30] and the improved transloca-
tion of homologous and heterologous preproteins [36]. Since
the increased thermolability of the SecYEG complex is not
manifested when the protein is functionally embedded in the
membrane, it appears that the phenomenon is detergent-in-
duced. It may well be that also in the membrane the SecY^
SecE interaction is altered, but this does not lead to thermo-
lability in a physiologically relevant temperature range. In
contrast, the altered SecA binding a⁄nity by PrlA mutants
is observed both with the membrane-embedded ([18], this
study) and detergent-solubilized complexes [29]. We therefore
propose that the primary e¡ect of the prlA mutations is the
modulation of the SecA binding a⁄nity rather than a relaxa-
tion of signal sequence recognition. The enhanced stability of
the SecA^SecY complex in the presence of ATP allows for an
improved initiation of translocation, which is re£ected by in-
creased rates of the translocation of normal and signal se-
quence defective preproteins [18]. The improved SecA binding
a⁄nity may well arise from an altered physical interaction
between SecY and SecE.
Biochemical and electron microscopy studies indicate that
upon the activation of SecA by the non-hydrolyzable ATP
analogue AMP^PNP, a large translocation pore is formed
that comprises four SecYEG complexes [23]. This process
mimics the ATP-dependent initiation of translocation in the
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absence of a preprotein [5]. Recruitment of SecYEG com-
plexes by SecA likely represents a critical step in the trans-
location reaction. A recent equilibrium ultracentrifugation
study suggests that PrlA4 forms more stable SecYEG dimers
as compared to wild-type SecYEG [38]. The increased SecA
binding a⁄nity and an altered oligomeric state of the idle
SecYEG complex may facilitate the SecA-mediated formation
of SecYEG tetramers. This would provide the PrlA4 mutant
with a kinetic advantage for translocation of preproteins as
compared to the wild-type. Alternatively, the enhanced SecA
binding may be a result of the increased stability of the PrlA4
mutant SecYEG dimer. Future studies should be directed to
analyze the dynamics of the assembly of the translocase com-
plex.
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